Search clinical trials for: BMS-354825

Total 1980 results

Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Svelte Medical Systems Europe

Terminated

Acrobat Coronary Stent System Effectiveness European Study (ACES)

Coronary Artery Disease

Spain, France, Belgium
Bristol-Myers Squibb

Completed

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Multiple Sclerosis (MS)

United States, United Kingdom
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
China National Center for Cardiovascular Diseases
Peking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...

Unknown

A New Classification and Interventional Therapy for Coronary Artery Ectasia (NCIPCAE)

Coronary Artery Ectasia

China
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb

Completed

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Gastric Cancer

China, Japan, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Systemic Lupus Erythematosus | Inflammatory Bowel Diseases | Psoriasis | Arthritic Psoriasis

United States
Dana-Farber Cancer Institute
Stand Up To Cancer

Active, not recruiting

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Lymphoma | Solid Tumor, Childhood | Brain Tumor, Pediatric

United States, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Bristol-Myers Squibb

Completed

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

Healthy Participants

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Healthy Volunteers

United Kingdom
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States, Italy, Australia, Poland, Spain
Taipei City Hospital

Completed

Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques (MV:main branch)

Stable Angina

Taiwan
Stentys

Terminated

Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V)

Acute Myocardial Infarction

Netherlands, United States
Bristol-Myers Squibb

Completed

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

United States, France, Spain, Germany
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Cancer

Switzerland
Biotronik AG

Completed

Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis (PEPPER)

In-stent Coronary Artery Restenosis

Germany
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

Heart Failure With Reduced Ejection Fraction

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants

Healthy Volunteer

United States
PETHEMA Foundation
Janssen-Cilag, S.A.; Celgene-BMS; LIDESEC

Not yet recruiting

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Multiple Myeloma

Spain
University of Nottingham

Completed

Protein Ingestion and Muscle Carnitine Uptake

Muscle, Skeletal
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Endometrial Adenocarcinoma | Endometrial Carcinosarcoma

United States
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid... and other conditions

United States
Bristol-Myers Squibb

Completed

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Depression

Japan
Bristol-Myers Squibb

Withdrawn

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Atherosclerotic Cardiovascular Disease
Bristol-Myers Squibb

Terminated

Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Canada
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

Absolute Bioavailability of BMS-791325

Hepatitis C Virus Infection

United Kingdom
S.M. Misericordia Hospital

Completed

Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions (DESERT)

Stable Coronary Artery Disease | Silent Myocardial Ischemia | In-stent(BMS)Restenosis | De-novo, Atherosclerotic, Coronary Lesions

Italy
Concure Oncology-Breast Microseed Inc.

Recruiting

A Registry Study of Breast Microseed Treatment

Breast Neoplasms

United States
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

Major Depressive Disorder

United States
Presidio Ospedaliero Garibaldi-Centro
University of Padova; University of Catania; Carlo Besta Neurological Institute

Completed

Botulinum Toxin in Burning Mouth Syndrome

Burning Mouth Syndrome
Kenneth H. Mayer, MD
Bristol-Myers Squibb; Gilead Sciences; Abbott

Terminated

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (BMS PEP)

HIV

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
The Netherlands Cancer Institute

Completed

ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (IMCISION)

Head and Neck Neoplasms | Immunotherapy

Netherlands

3

Subscribe